Opendata, web and dolomites

ReMedPsy SIGNED

Re-emerging Magic Molecules: The Medicalization of Psychedelics in the United States

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ReMedPsy project word cloud

Explore the words cloud of the ReMedPsy project. It provides you a very rough idea of what is the project "ReMedPsy" about.

science    interplay    again    ptsd    responsible    sociotechnical    drug    introduction    sts    yield    regulations    molecules    health    policy    controversial    decades    western    psychedelics    psilocybin    treating    frame    mdma    revival    methodology    co    enabled    public    integration    1930s    60s    coming    category    constellations    insights    mental    actors    culture    benefit    risk    governments    contemporary    medicines    model    evaluations    indicated    psychedelic    actor    medical    2000    lsd    depression    restrictive    researcher    began    recommendations    changed    threat    investigates    addiction    career    policies    highlighting    traces    scientific    complete    classifications    qualitative    abuse    society    placed    socio    center    ketamine    standstill    re    regard    1960s    scientists    political    training    deepen    accepted    nor    substances    significantly    transfer    fostered    psychiatric    licensed    imaginaries    ascribing    explores    forefront    slowly    country    almost    see   

Project "ReMedPsy" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITAT WIEN 

Organization address
address: UNIVERSITATSRING 1
city: WIEN
postcode: 1010
website: www.univie.ac.at

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Austria [AT]
 Total cost 261˙208 €
 EC max contribution 261˙208 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-GF
 Starting year 2018
 Duration (year-month-day) from 2018-08-01   to  2021-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAT WIEN AT (WIEN) coordinator 261˙208.00
2    PRESIDENT AND FELLOWS OF HARVARD COLLEGE US (CAMBRIDGE) partner 0.00

Map

 Project objective

This proposal presents a research-via-training project that will transfer knowledge from the U.S. to Europe and allow the experienced researcher to deepen her study of (re-)emerging scientific fields to advance her career significantly. The project explores how scientists and other actors currently re-frame psychedelics in a scientific model to make them into licensed medicines. Since their introduction into Western science and culture (1930s-60s), psychedelic substances such as psilocybin or LSD have been highly controversial. Although early research indicated promising psychiatric applications, Western governments began to see psychedelics as a threat to public health in the 1960s and placed them into the most restrictive drug category, ascribing them a high potential for abuse and no currently accepted medical use. After coming to an almost complete standstill for several decades, psychedelic research is slowly re-emerging since 2000, highlighting again their potential for treating mental health issues such as addiction, depression, or PTSD. Since neither the molecules nor regulations have changed, this project investigates which socio-political conditions have enabled this revival (e.g., changes in the scientific or broader culture, risk-benefit evaluations). It traces how the responsible re-integration of psychedelics is fostered through the interplay of actor constellations, the production of scientific knowledge, and sociotechnical imaginaries. Using a qualitative research methodology and approaches from Science and Technology Studies (STS), it focuses on three molecules that are at the center of contemporary research in the U.S. (the country currently at the forefront of psychedelic research): MDMA, psilocybin, and ketamine. The project results will yield important insights into how psychedelic science and society are co-produced, and provide timely policy recommendations with regard to drug classifications, and drug and public health policies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "REMEDPSY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "REMEDPSY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MultiSeaSpace (2019)

Developing a unified spatial modelling strategy that accounts for interactions between species at different marine trophic levels, and different types of survey data.

Read More  

ActinSensor (2019)

Identification and characterization of a novel damage sensor for cytoskeletal proteins in Drosophila

Read More  

ASSEMBLY (2019)

Advancing Synthethic Supramolecular chemical biology

Read More